CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

OTSUKA

OTSKF
$38.82BLarge Cap

Next catalyst

Phase 2February 2027

Bedaquiline (B)

Pulmonary Tuberculosis

Get an email about OTSKF's next catalysts

Track OTSUKA (OTSKF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 6 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

7 upcoming, 2 past

Phase 2Next

Bedaquiline (B) Phase 2 Est. Readout (PARADIGM4TB)

February 2027~Bedaquiline (B)2,500

Estimated primary completion for Bedaquiline (B) trial (NCT06114628) in Pulmonary Tuberculosis. Topline data typically follows completion by weeks to months.

Source
Phase 2

Sibeprenlimab Phase 2 Est. Readout (EnVISage)

March 2027~Sibeprenlimab83

Primary completion for Sibeprenlimab trial (NCT06928142) in Sjogren Disease

Source
Phase 2

IRL757 Phase 2 Est. Readout (LIFT-PD)

May 2027~IRL75775

Estimated primary completion for IRL757 trial (NCT07461220) in PARKINSON DISEASE (Disorder). Topline data typically follows completion by weeks to months.

Source
Phase 3

Centanafadine XR Phase 3 Est. Readout

Q2 2027~QCentanafadine XR80

Estimated primary completion for Centanafadine XR trial (NCT07759154) in Attention-deficit/Hyperactivity Disorder. Topline data typically follows completion by weeks to months.

Source
Phase 3

EB-1020 (Centanafadine) low dose Phase 3 Est. Readout

August 2027~EB-1020 (Centanafadine) low dose315

Primary completion for EB-1020 (Centanafadine) low dose trial (NCT07087327) in Attention-Deficit Hyperactivity Disorder(ADHD)

Source
Phase 3

OPC-34712FUM/Brexpiprazole fumarate Phase 3 Est. Readout

September 2027~OPC-34712FUM/Brexpiprazole fumarate450

Estimated primary completion for OPC-34712FUM/Brexpiprazole fumarate trial (NCT05325645) in Acute Schizophrenia. Topline data typically follows completion by weeks to months.

Source
Phase 3

JNT-517 Phase 3 Est. Readout

Q4 2027~QJNT-517240

Primary completion for JNT-517 trial (NCT06628128) in Phenylketonuria (PKU)

Source

Market Overview

Stock performance and key metrics

NASDAQHealthcare🇺🇸North America37.8K employees
Drug Pipeline

Tolvaptan (OPC-41061)

Phase 3

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

OPC-34712

Phase 3

Schizophrenia

Cilostazol

Phase 3

Vasospastic Angina

Centanafadine Hydrochloride

Phase 3

Attention-Deficit/Hyperactivity Disorder

AVP-786

Phase 3

Agitation in Patients With Dementia of the Alzheimer's Type

EB-1020 (Centanafadine)

Phase 3

Attention Deficit Hyperactivity Disorder (ADHD)

CDP870

Phase 3

Rheumatoid Arthritis

Centanafadine

Phase 3

Major Depressive Disorder

Tolvaptan Suspension

Phase 3

Autosomal Recessive Polycystic Kidney (ARPKD)

Hyalein Mini Ophthalmic solution

Phase 3

Dry Eye Syndromes

SEP363856

Phase 3

Schizophrenia

JNT-517

Phase 3

Phenylketonuria (PKU)

Antidepressant therapy

Phase 3

Major Depressive Disorder

OPC-41061(Tolvaptan)

Phase 3

Cardiac Edema

Ropinirole

Phase 3

Parkinson's Disease

Tolvaptan Oral Tablet

Phase 3

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Aripiprazole orally

Phase 3

Schizophrenia

Meptin swinghaler

Phase 3

Asthma

Valproate

Phase 3

Bipolar Disorder Mania

Aripiprazole (Fixed dose)

Phase 3

Major Depressive Disorder

Quetiapine extended release

Phase 3

Schizophrenia

Aripiprazole

Phase 3

Schizophrenia

Tolvaptan Tablets

Phase 3

Autosomal Recessive Polycystic Kidney (ARPKD)

Busulfan

Phase 3

Multiple Myeloma

Aripiprazole (BMS-337039)

Phase 3

Dementia, Alzheimer Type

Aripiprazole+ ADT

Phase 3

Major Depressive Disorder

Olanzapine or Quetiapine or Risperidone

Phase 3

Schizophrenia

TEV-48125

Phase 3

Migraine

Antidepressant + Aripiprazole

Phase 3

Major Depressive Disorder

Procaterol, Salbultamol

Phase 3

Moderate Acute Asthma

Vadadustat

Phase 3

Anemia

OPC-12759 Ophthalmic suspension

Phase 3

Dry Eye Syndromes

Aripiprazole Low

Phase 3

Schizophrenia

Paroxetine CR

Phase 3

Depressive Disorder

Aripiprazole and aripiprazole once-monthly

Phase 3

Schizophrenia

OPC-6535

Phase 3

Crohn's Disease

OPC-34712FUM/Brexpiprazole fumarate

Phase 3

Acute Schizophrenia

Aripiprazole Oral Solution

Phase 3

Autistic Disorder

Aripiprazole (Abilify®) IM Depot Injection

Phase 3

Schizophrenia

OPC-34712 + ADT

Phase 3

Depressive Disorder

Aripiprazole IM Depot

Phase 3

Schizophrenia

Aripiprazole High

Phase 3

Schizophrenia

Asacol®

Phase 3

Ulcerative Colitis

AVP-786-18

Phase 3

Agitation in Participants With Dementia of the Alzheimer's Type

BPaQM

Phase 3

Pulmonary Tuberculosis

ETC-1002(bempedoic acid)

Phase 3

Hyper-low-density Lipoprotein (LDL) Cholesterolemia

Aripiprazole Mid

Phase 3

Schizophrenia

Aripiprazole (Titrated dose)

Phase 3

Major Depressive Disorder

Oral decitabine/cedazuridine

Phase 3

Myelodysplastic Syndromes

AVP-786-42.63

Phase 3

Agitation in Participants With Dementia of the Alzheimer's Type

Aripiprazole tablet

Phase 3

Schizophrenia

Centanafadine SR

Phase 3

Attention Deficit Disorder

Seroquel XR

Phase 3

Depressive Disorder

OPC-34712 Middle Dose

Phase 3

Acute Schizophrenia

OPC-34712 Low Dose

Phase 3

Acute Schizophrenia

Brexpiprazole, OPC-34712

Phase 3

Agitation Associated With

Mucosta Tab

Phase 3

Acute Gastritis

Subcutaneous azacitidine

Phase 3

Myelodysplastic Syndromes

Isoniazid (INH)

Phase 3

Tuberculosis, MDR

OPC-14597 (Aripiprazole)

Phase 3

Major Depressive Disorder

OPC-41061 (Tolvaptan)

Phase 3

Cardiac Edema

Aripiprazole depot

Phase 3

Schizophrenia

Escitalopram

Phase 3

Depressive Disorder

OPC-34712 High Dose

Phase 3

Acute Schizophrenia

Latanoprost ophthalmic solution

Phase 3

Glaucoma

OPC-6535 Tablets (drug)

Phase 3

Ulcerative Colitis

MCT-SR

Phase 3

Acute Gastritis

Abilify (Tablet)

Phase 3

Depression, Bipolar

High Dose Melphalan

Phase 3

Myeloma

Delamanid (DLM)

Phase 3

Tuberculosis, MDR

Rebamipide and Omeprazole

Phase 3

Gastric Ulcer

Meptin® Swinghaler

Phase 3

Asthma

OPC-1085EL ophthalmic solution

Phase 3

Glaucoma

Rebamipide

Phase 3

Keratoconjunctivitis Sicca

JNT-517 Tablet

Phase 3

Phenylketonuria (PKU)

Tolvaptan

Phase 3

Congestive Heart Failure

EB-1020 (Centanafadine) low dose

Phase 3

Attention-Deficit Hyperactivity Disorder(ADHD)

Nalmefene hydrochloride

Phase 3

Alcohol Dependence

Misoprostol

Phase 3

Rheumatoid Arthritis

OPC-1085EL

Phase 3

Open Angle Glaucoma or Ocular Hypertension

Venlafaxine XR

Phase 3

Depressive Disorder

Sibeprenlimab

Phase 3

IgA Nephropathy

OPC-12759

Phase 3

Dry Eye

Centanafadine XR

Phase 3

Attention-deficit/Hyperactivity Disorder

Ventolin® MDI

Phase 3

Asthma

Haloperidol

Phase 3

Bipolar Disorder

Brexpiprazole +ADT

Phase 3

Depressive Disorder

ADT

Phase 3

Major Depressive Disorder

EB-1020 (Centanafadine) high dose

Phase 3

Attention-Deficit Hyperactivity Disorder(ADHD)

Delamanid + OBR

Phase 3

Multidrug-resistant Tuberculosis

centanafadine capsule

Phase 3

Attention Deficit/Hyperactivity Disorder

Each subject will subcutaneously self-administer TEV 48125 at/monthly for a total of 2 doses

Phase 3

Migraine

Probucol

Phase 3

Hyperlipidemia

OPC-41061

Phase 3

Cirrhosis

SEP-363856

Phase 3

Schizophrenia

OPC-61815 injection

Phase 3

Congestive Heart Failure

ASC-01

Phase 3

Major Depressive Disorder

Certolizumab Pegol

Phase 3

Rheumatoid Arthritis

Lithium

Phase 3

Bipolar Disorder Mania

AVP-786-28

Phase 3

Neurobehavioral Disinhibition

OPA-15406

Phase 3

Atopic Dermatitis

OPC-61815

Phase 3

Congestive Heart Failure

Quabodepistat

Phase 3

Rifampicin-Resistant Pulmonary Tuberculosis

Brexpiprazole (OPC-34712)

Phase 3

Schizophrenia

Bedaquiline

Phase 3

Tuberculosis, Multidrug-Resistant

SPM 962

Phase 3

Idiopathic Restless Legs Syndrome

Pretomanid

Phase 3

Rifampicin-Resistant Pulmonary Tuberculosis

Brexpiprazole

Phase 3

Major Depressive Disorder

only Decitabine and cedazuridine

Phase 2

Myelodysplastic Syndromes

OPB-31121 phase2

Phase 2

Hepatocellular Carcinoma

Graft versus Host Disease prevention (GVHD prophylaxis)

Phase 2

Hematological Malignancies

Clofazimine

Phase 2

Tuberculosis, Multidrug-Resistant

High Dose-VIS649

Phase 2

Immunoglobulin A Nephropathy

OCV-501

Phase 2

Acute Myeloid Leukemia

Sodium hyaluronate ophthalmic solution

Phase 2

Keratoconjunctival Epithelial Disorder

Delamanid + Bedaquiline + OPC-167832

Phase 2

Pulmonary TB

OPB-31121

Phase 2

Hepatocellular Carcinoma

OPC-64005

Phase 2

Adult Attention Deficit Hyperactivity Disorder

OPC-249

Phase 2

Pain Due to Osteoporosis

IV busulfan

Phase 2

Multiple Myeloma

Optimized Background Regimen (OBR)

Phase 2

Tuberculosis, Pulmonary

13C-uracil

Phase 2

Dyspeptic Subjects

tetomilast (OPC-6535)

Phase 2

Chronic Obstructive Pulmonary Disease

Delamanid

Phase 2

Tuberculosis, Multidrug-Resistant

OPC-167832

Phase 2

Pulmonary TB

CTN SR

Phase 2

Attention Deficit Disorder With Hyperactivity

Cilostazol, Probucol

Phase 2

Peripheral Artery Disease

IV Decitabine

Phase 2

Myelodysplastic Syndromes

OPC-12759 ophthalmic

Phase 2

Dry Eye Syndromes

Calcium (13C)Carbonate

Phase 2

Gastric Acid-related Diseases

Gastric acid inhibitors

Phase 2

Gastroesophageal Reflux Disease

Tolvaptan MR

Phase 2

Autosomal Dominant Polycystic Kidney Disease

Tolvaptan IR

Phase 2

Autosomal Dominant Polycystic Kidney Disease

OPC-18

Phase 2

Hepatocellular Carcinoma

OPS-2071 tablet

Phase 2

Bacterial Enteritis

99mTc sulfur colloid

Phase 2

Dyspeptic Subjects

Delamanid Pediatric Formulation (DPF)

Phase 2

Multidrug Resistant Tuberculosis

OPC-67683

Phase 2

Pulmonary Tuberculosis

Rebamipide liquid

Phase 2

Head and Neck Cancer

OPS-2071

Phase 2

Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Vesnarinone

Phase 2

Sarcoma, Kaposi

IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)

Phase 2

Lymphoma

OPC 131461 group

Phase 2

Cardiac Edema (CHF)

OPC-167832 + delamanid

Phase 2

Pulmonary TB

Low Dose-VIS649

Phase 2

Immunoglobulin A Nephropathy

OPC-167832 + BDQ

Phase 2

Pulmonary TB

Rifafour e-275

Phase 2

Pulmonary Tuberculosis

OPC-167832 + delamanid + BDQ

Phase 2

Pulmonary TB

Stimulant Therapy

Phase 2

Attention Deficit Hyperactivity Disorder

therapeutic allogeneic lymphocytes

Phase 2

Chronic Myeloproliferative Disorders

Rexulti

Phase 2

Borderline Personality Disorder

AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)

Phase 2

Depressive Disorder, Treatment-Resistant

Ponatinib OD

Phase 2

Chronic Myeloid Leukemia

OPDC-34712

Phase 2

Attention Deficit Hyperactivity Disorder

OPC-415

Phase 2

Multiple Myeloma (MM)

JNT-517 Suspension

Phase 2

Phenylketonuria

rabbit anti-thymocyte globulin (ATG)

Phase 2

Chronic Myeloproliferative Disorders

Aripiprazole + IEM (Ingestible Event Marker)

Phase 2

Schizophrenia

Busulfan, Fludarabine, Cytoxan

Phase 2

Lymphoma

busulfan, melphalan and fludarabine

Phase 2

Multiple Myeloma

PB

Phase 2

Autosomal Dominant Polycystic Kidney Disease

High-dose chemotherapy

Phase 2

Non-Hodgkin's Lymphoma

Flu/Bu4 conditioning regimen

Phase 2

Hematological Malignancies

OBR

Phase 2

Tuberculosis, Multidrug-Resistant

Linezolid (L)

Phase 2

Pulmonary Tuberculosis

Delpazolid (DZD)

Phase 2

Pulmonary Tuberculosis

Bedaquiline (B)

Phase 2

Pulmonary Tuberculosis

Aripiprazole tablet,, oral, 6 weeks

Phase 2

Schizophrenia

Risperidone tablet,, oral, 6 weeks

Phase 2

Schizophrenia

Moxifloxacin (M)

Phase 2

Pulmonary Tuberculosis

Delamanid (D)

Phase 2

Pulmonary Tuberculosis

Pretomanid (Pa)

Phase 2

Pulmonary Tuberculosis

Linezolid

Phase 2

Tuberculosis, Multidrug-Resistant

BTZ-043

Phase 2

Pulmonary Tuberculosis

Pyrazinamide (Z)

Phase 2

Pulmonary Tuberculosis

Quabodepistat (Q)

Phase 2

Pulmonary Tuberculosis

Optimized multidrug background regimen (OBR) for children with MDR-TB

Phase 2

Tuberculosis

Clofarabine/Busulfan x 4

Phase 2

Acute Myeloblastic Leukemia

IRL757

Phase 2

PARKINSON DISEASE (Disorder)

OPC-41601

Phase 2

Cirrhosis

Decitabine and cedazuridine

Phase 2

Myelodysplastic Syndromes

Medium Dose-VIS649

Phase 2

Immunoglobulin A Nephropathy

Frequently asked questions

What is in OTSUKA's drug pipeline?→

CatalystAlert tracks 182 drug candidates in OTSUKA's (OTSKF) pipeline across Phase 3, Phase 2. Its lead program is Centanafadine XR (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is OTSUKA's next FDA catalyst?→

OTSUKA's (OTSKF) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track OTSKF biotech catalysts?→

Add OTSKF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OTSUKA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply